Related by context. All words. (Click for frequent words.) 69 initiate Phase IIb 66 initiate Phase Ib 65 Onyx Pharma 65 BLA filing 63 initiate Phase 2b 63 phase IIa clinical 62 Phase IIIb clinical 61 initiated Phase Ib 61 TOCOSOL Paclitaxel 61 Auxilium Pharma 61 phase IIb 61 SCHEDULED TO PREMIERE 61 GALNS 61 Isis Pharma 60 pivotal bioequivalence 60 refractory acute lymphoblastic 60 ruxolitinib 60 phase IIa 60 Phase IIb trials 60 phase IIb clinical 60 FlutiformTM 60 elotuzumab 60 Earnings Preview Activision Blizzard 60 PRECISE trial 60 Phase 1a clinical 60 PEG PAL 59 initiate Phase 1b 59 Tocosol Paclitaxel 59 Phase Ib clinical 59 oral ridaforolimus 59 INCB# [001] 59 UPLYSO 59 PF # [002] 59 Corlux 59 Phenoptin 59 ENDEAVOR III 59 WILEX 59 GetGoal Phase III 59 Phase Ib II 59 CIP TRAMADOL ER 59 confirmatory Phase III 59 Troxatyl 59 deforolimus 58 Adventrx 58 PREOS R 58 SUCCEED trial 58 initiate Phase IIa 58 IND submission 58 bicifadine 58 BRIM3 58 Phase 2b trial 58 Phase 1b trial 58 Pivotal Phase III 58 Phase IIb clinical trials 58 IIa trial 58 midstage trials 58 Phase Ib study 58 APEX PD 57 Phase IIb clinical 57 Phase #b/#a 57 Phase IIB 57 Earnings Preview Bristol Myers 57 Annamycin 57 HGS# 57 Ereska 57 EndoTAG TM -1 57 phase 2a 57 MOZOBIL 57 Phase 2a trial 57 Phase 2a clinical 57 SPARLON 57 Phase Ib 57 PDE4 inhibitor 57 ponatinib 57 omacetaxine mepesuccinate 57 Phase 2b clinical 57 Phase 2b clinical trials 57 Orathecin 57 Phase IIa trial 57 JAK inhibitor 57 Dyloject TM 56 Zensana 56 Phase 1b clinical 56 AMPAKINE CX# 56 Camvia 56 LAF# 56 Phase 1a 56 Phase IIb trial 56 Neurosearch 56 Zenvia ™ 56 Ziopharm 56 SNS# T 56 brivaracetam 56 Earnings Preview KB Home 56 ITAX 56 cannabinor 56 maribavir 56 Thorough QT 56 Marketing Authorisation Application MAA 56 Earnings Preview Toll Brothers 56 CB2 selective receptor agonist 56 OvaRex 56 trastuzumab DM1 T DM1 56 registrational trial 56 Phase IIb 56 phase IIb study 56 lomitapide 56 Targretin 56 unblinding 56 PMA submission 56 PANVAC VF 56 OncoVEX 56 Sigma Tau SpA 56 Hovnanian trims 56 Hedgehog antagonist 56 PTK ZK 56 Bicifadine 56 BLOOM DM 56 phase Ib 56 Phase 2b study 56 Inspire Pharma 56 Junovan 56 Omigard 56 zileuton CR 55 generic Lovenox 55 CLIRS trial 55 TBC# 55 Preos 55 NSABP C 55 MAA submission 55 CRMD# 55 balsalazide tablet 55 Luveniq 55 Memryte 55 Loramyc 55 ENDEAVOR IV 55 Civacir 55 Velcade bortezomib 55 Genentech Roche 55 Nexavar sorafenib 55 PREOS 55 Vion Pharmaceuticals 55 GLP toxicology studies 55 PREGNANT Study 55 alvespimycin 55 Flutiform ™ 55 registrational 55 CRTX 55 dose escalation Phase 55 Marketing Authorisation Application 55 GSK# [002] 55 Somatuline R Autogel R 55 OvaRex R 55 pivotal Phase III 55 BLA submission 55 Amrubicin 55 ridaforolimus 55 Phase 1b 55 zanolimumab 55 teduglutide 55 Sanctura XR 55 Ambrisentan 55 Zenvia Phase III 55 Phase IIa trials 55 Zybrestat 55 EPS Excl 55 Factor VIIa 55 assessing T DM1 55 Phase IIa clinical 55 Alvesco R 55 Initiate Phase 55 Vicriviroc 55 Firdapse 55 IND enabling 55 PLK1 SNALP 55 Phase 2b randomized 55 Huntexil 54 investigational humanized monoclonal antibody 54 Voraxaze 54 AVADO 54 DPX Survivac 54 DepoMed 54 MEND CABG II 54 NDA resubmission 54 TOLAMBA 54 FDA approvable letter 54 IND CTA 54 PHASE III 54 confirmatory Phase 3 54 SinuNase ™ 54 Solzira 54 TEMSO 54 R#/MEM # 54 fidaxomicin Phase 3 54 narrows Quick Facts 54 ORAL Sync 54 PEP# [003] 54 rALLy trial 54 MyVax 54 Phase IIb III 54 diabetic neuropathic pain 54 Files Investigational 54 Phase III Clinical Trial 54 randomized Phase 2b 54 Aegerion 54 FFO Declines 54 ZOLINZA 54 initiate Phase 54 anidulafungin 54 vidofludimus 54 Curagen 54 Genz # 54 Earnings Preview EBay 54 dextromethorphan quinidine 54 LE SN# 54 Phase III 54 Icatibant 54 liprotamase 54 Marqibo 54 Gattex 54 MAP Pharma 54 StaphVAX 54 acyclovir Lauriad R 54 glucokinase activator 54 Par Pharma 54 LidoPAIN SP 54 rALLy 54 Backs FY# Adj 54 MEND CABG 54 non nucleoside inhibitor 54 CONBRIZA 54 Phase IIa 54 DPP4 inhibitor 54 Enzon Pharma 54 NDA Submission 54 CIP ISOTRETINOIN 54 intravenous acetaminophen 54 iniparib 54 teriflunomide 54 Asenapine 54 Dynogen 54 Ketotransdel 54 NeuroSearch 54 IV APAP 54 inhaled AAT 53 Canvaxin 53 dirucotide 53 Dextofisopam 53 IIa trials 53 Phase III clinical 53 Arpida 53 Cimzia TM 53 Glybera R 53 NDA submission 53 seliciclib CYC# 53 AERx iDMS 53 Urocidin 53 Tykerb lapatinib 53 fidaxomicin Phase 53 Ixempra 53 Pruvel 53 Cubist Pharma 53 phase Ib clinical 53 T Pred 53 Zadaxin 53 SPRYCEL ® 53 GLPG# 53 Sulonex TM 53 Phase III pivotal 53 CLIRS 53 Cloretazine ® 53 Phase III trials 53 BRILINTA 53 indiplon capsules 53 BRIM2 53 Tesmilifene 53 oral methylnaltrexone 53 Plicera 53 Aplidin 53 NVA# 53 AEG# 53 bardoxolone 53 cabozantinib 53 Earnings Preview IAC 53 tramiprosate Alzhemed TM 53 PEG SN# 53 KRYSTEXXA TM pegloticase 53 Clinuvel 53 Velac 53 preclinical pharmacokinetic 53 nonclinical studies 53 Zenpep 53 cathepsin K inhibitor 53 Mipomersen 53 Acapodene 53 Phase 2b 53 UCB Cimzia 53 Phase IIIb 53 celgosivir 53 sBLA 53 Vilazodone 53 tafamidis 53 IL# PE#QQR 53 Phase 2a clinical trials 53 AQ4N 53 Q#/FY# 53 Oglemilast 53 Soliris eculizumab 53 torezolid phosphate 53 dalbavancin 53 relapsed acute lymphocytic 53 Phase Ia 53 amrubicin 53 trastuzumab DM1 53 PRIMO CABG 53 PDX pralatrexate 53 PSN# [002] 53 cystinosis patients 53 sNDA submission 53 hoFH 53 ONCONASE R 53 QLT# 53 bazedoxifene 53 Phase IIA 53 PPD Nasdaq PPDI 53 dose escalation clinical 52 ICA # 52 aflibercept 52 FTY# fingolimod 52 Bifeprunox 52 Aryx 52 Teveten 52 Arcalyst 52 Phase 2a 52 Troxatyl TM 52 faropenem 52 Phase III Pivotal 52 Intermezzo ® NDA 52 confirmatory clinical 52 Stavzor 52 RhuDex 52 Atherogenics 52 Net Profit Dips 52 DASISION 52 Biologic License Application 52 IMA# 52 Indiplon 52 desvenlafaxine 52 Panzem 52 Solasia 52 Phase 2b monotherapy 52 ularitide 52 Progenics Pharmaceuticals 52 Glybera 52 reslizumab 52 ATHX 52 histamine dihydrochloride 52 ALN PCS 52 sterile lidocaine patch 52 IMPACT IMmunotherapy 52 ATL# [001] 52 Phase #b/#a clinical 52 Phase #b/#a trial 52 Ranexa 52 Phase lll 52 Randomized Phase 52 Earnings Preview CarMax 52 Onconase 52 Colazal 52 Shigamabs 52 adecatumumab MT# 52 Spiegelmer ® 52 Alzhemed TM 52 perifosine KRX 52 Zenvia TM 52 NanoKnife IRE System 52 EPCT 52 Phase #/#a trial 52 rThrombin 52 Homebuilder Lennar posts 52 iloperidone 52 FDA Approvable Letter 52 Archexin 52 HCV RESPOND 2 52 INCB# [002] 52 Fx #A 52 JZP 52 severe hypercholesterolemia 52 Initiated Phase 52 Meets Primary Endpoint 52 MAXY VII 52 AMD# [002] 52 Phase IIb Trial 52 Tezampanel 52 Loramyc R 52 Dalbavancin 52 XL# SAR# 52 Bonefos 52 Firazyr 52 Biologic License Application BLA 52 Panzem R 52 Enobia 52 virus HCV protease inhibitor 52 tasimelteon 52 gepirone ER 52 AP# [003] 52 Trexima 52 Corcept 52 ILLUMINATE 51 Pivotal Phase 51 unblind 51 ganetespib 51 BEMA TM Fentanyl 51 almorexant 51 SILENOR TM 51 PrevOnco 51 Cloretazine R 51 Narrows Quick Facts 51 Nexavar ® 51 Fodosine 51 submit Biologics License 51 ALGRX 51 tiapamil 51 Completes Patient Enrollment 51 RESTORE CLI 51 TASKi2 51 Clinical Trials Review 51 HspE7 51 Jevtana 51 GRAVITAS trial 51 Salix Pharma 51 Cloretazine R VNP#M 51 Phase 2b Clinical Trial 51 PS# [001] 51 EOquin TM 51 ABX EGF 51 omacetaxine 51 LibiGel ® 51 outlicensing 51 PSMA ADC 51 alvimopan 51 Topical Interferon Alpha 2b 51 lexidronam injection 51 Aryplase 51 NEBIDO 51 ANDA filings 51 widens Quick Facts 51 Omapro 51 Loss Shrinks 51 Nebido 51 RH1 51 Initiates Phase II 51 Net Profit Triples 51 ATryn R 51 SPIRIT FIRST 51 Kahalalide F 51 Omacetaxine 51 Angiocept 51 NASDAQ ARRY 51 Developmental Therapeutics Review 51 Flutiform 51 Xanafide 51 Osiris Therapeutics 51 Alnara 51 alogliptin 51 QuatRx 51 ocular formulation 51 Vorapaxar 51 Avanir 51 illumigene 51 generation PNP inhibitor 51 Anturol TM 51 ImClone Erbitux 51 Reiterates Guidance 51 Theratope 51 Vicuron Pharmaceuticals 51 Betaferon multiple sclerosis 51 DDP# 51 FIRMAGON R 51 Matrix Phase 2b 51 Novolimus 51 Biologics License Application BLA 51 Phase IIb Clinical Trial 51 LymphoStat B belimumab 51 ToGA 51 TRANSDUR Bupivacaine 51 Santhera 51 Cipralex ® 51 ANTEGREN 51 Sanvar 51 HDAC Inhibitor 51 ARRY # 51 OSI Pharma 51 investigational antiplatelet agent 51 Anavex #-# 51 Fesoterodine 51 maturation inhibitor 51 preclinical pharmacology 51 Pafuramidine 51 ILUVIEN ® 51 HoFH 51 Earnings Preview Yum Brands 51 Loss Reduces 51 Alvesco 51 Onrigin 51 #Q/#Q 51 APF# 51 apricitabine ATC 51 Phase III randomized controlled 51 Vertex hepatitis C 51 Complete Response 51 EVIZON TM 51 Phase #/#a 51 novel histone deacetylase 51 sumatriptan injection 51 IIb clinical trial 51 Menerba 51 opioid induced bowel dysfunction 51 miconazole Lauriad 51 Indevus Pharma 51 CLARITY study 51 bifeprunox 51 Erbitux cetuximab 51 Onco TCS 51 IND Investigational New 51 PROVENGE sipuleucel T 50 IMC #B 50 TELINTRA 50 revises FY# 50 Pradefovir 50 Milestone Payments 50 palifosfamide Zymafos TM 50 Arzerra ofatumumab 50 Earnings Release Scheduled 50 IMPACT DCM 50 TriLipix 50 Fast Tracked Phase 50 placebo controlled Phase 50 OMAPRO ™ 50 amifampridine phosphate 50 Sanvar R 50 CCR9 antagonist 50 blood thinner Xarelto 50 LEP ETU 50 RhuDex ® 50 HepeX B 50 supplemental biologics 50 Biomarin 50 PRE SURGE 50 Protalex 50 Altana AAA 50 lifts FY# EPS 50 Gralise 50 Rhucin 50 preclinical efficacy 50 OMAPRO 50 Marketing Authorization Application 50 EDEMA3 trial 50 GENASIS clinical 50 varespladib 50 B. Lynne Parshall 50 ACUITY trial 50 Dyloject 50 reaffirms FY# 50 evaluating mipomersen 50 vilazodone 50 Gentamicin Surgical Implant 50 trastuzumab emtansine T DM1 50 Lauren Silvernail 50 Flutiform TM 50 lorvotuzumab mertansine 50 Oporia 50 JZP 6 50 confirmatory pivotal 50 PEARL HF 50 Initiate Clinical Trial 50 QRxPharma 50 Valtropin 50 Successfully Completes Phase 50 Amoxicillin PULSYS 50 inhaled formulation 50 tezampanel 50 CoTherix 50 Xyotax 50 Ruconest 50 Orazol 50 Manja Bouman CEO 50 metastatic hormone refractory 50 refractory APL 50 Xinlay 50 small molecule tyrosine 50 generic Allegra 50 investigational HCV polymerase 50 Orapred ODT 50 FOLOTYN ® 50 Personalized Immunotherapy 50 PARTNER Trial 50 ATL/TV# 50 Trofex 50 Strativa 50 SCIB1 50 mertansine 50 Volterra Semi 50 ostarine 50 tezampanel NGX# 50 Nasdaq NPSP announced 50 NASDAQ CXSP announced 50 Soliris TM eculizumab 50 voreloxin 50 outlicensed 50 Phoqus 50 TMC# [002] 50 HCV protease inhibitor 50 oral prodrug 50 Rapinyl 50 Surfaxin LS 50 AIR inhaled insulin 50 Ceflatonin R 50 Nasdaq VRTX 50 VIAject 50 Teva Pharma 50 triphendiol 50 cladribine tablets 50 Phase 2b RESTORE CLI 50 beta 1a 50 APF# NDA 50 Japanese Encephalitis vaccine 50 Evoltra R 50 clevudine 50 BiolineRX 50 MEK inhibitor 50 Leukine 50 Laquinimod 50 Lodotra 50 AzaSite Plus 50 torezolid 50 Biologics License Application 50 Ozarelix 50 Ambrilia Biopharma 50 elacytarabine 50 MelaFind pivotal 50 Augment Injectable 50 Marketing Authorization Application MAA 50 DOV Pharmaceutical 50 Egrifta 50 orally administered inhibitor 50 INC# 49 huN# DM1 49 budesonide MMX Phase III 49 VEGF Trap 49 Rhucin R 49 Proteo 49 Oracea 49 lucinactant 49 ZYBRESTAT TM 49 Napo Pharmaceuticals 49 Neurobiological Technologies 49 R# #mg BID 49 Pharmexa 49 Panzem ® 49 selective androgen receptor modulator 49 histone deacetylase HDAC inhibitor 49 Antegren 49 Lenocta TM 49 Hematide ™ peginesatide 49 Addrenex 49 Shipment Destination 1Q 49 Cenestin 49 multicenter Phase 49 Phase IIa proof 49 Commence Phase 49 methylnaltrexone 49 ATryn ® 49 Octreotide 49 UVIDEM 49 Shigamabs ® 49 Solution Provider 1Q 49 viral kinetic 49 Enjuvia 49 Frova ® 49 Dynavax 49 EOquin 49 Posts Narrower Loss 49 Valeant Pharma 49 Vimpat ® lacosamide 49 LEVADEX ™ 49 OncoVEX GM CSF 49 OPT CHF 49 CALGB # [002] 49 Revises FY# Outlook 49 XOMA 3AB 49 Maribavir 49 TRX1 49 Cellegesic 49 Altus Pharmaceuticals 49 Atelvia 49 ALKS 49 Decapeptyl 49 Phase III ADT 49 Serono SRA 49 Vascular Disrupting Agent 49 LIVALO 49 FoldRx 49 Syntonix 49 Net Profit Surges 49 Cannabinor 49 HEPLISAV TM 49 mTOR inhibitor 49 StemEx R 49 USD #.#mln 49 NASDAQ CLDX 49 PCI ExTRACT TIMI 49 Taranabant 49 Afresa 49 transmucosal delivery system 49 ARIKACE ™ 49 Investigational Oral 49 Eligard ® 49 peginesatide 49 RELOVAIR ™ 49 Backs FY# Forecast 49 CureTech 49 anticancer compound 49 Recentin 49 Nasdaq NYMX 49 OLpur TM H2H 49 CUSTOM III 49 RhuDex TM 49 TKM ApoB 49 non nucleoside HCV 49 Dificid 49 elvucitabine 49 AcelRx 49 inhaled liposomal ciprofloxacin 49 IGXT IntelGenx today 49 pharmacokinetic PK 49 Quick Facts2 49 vivo toxicology 49 immunotherapeutic vaccine 49 Amrix 49 apaziquone 49 Difimicin 49 molecular imaging radiopharmaceutical 49 Oncoscience AG 49 Cinryze ™ 49 Stedesa 49 Pivotal Phase II 49 PSN# [001] 49 Schering SHR 49 IIa clinical 49 Luveris 49 rhC1INH 49 initiate multicenter 49 silodosin 49 ALD# 49 EVIZON ™ 49 XL# anticancer compounds 49 Curaxin 49 Davanat 49 LUMINATE 49 ZURICH AFX Novartis AG 49 Ceflatonin 49 FavId 49 Lorqess 49 Phase Ib clinical trials 49 DermTech International 49 LUCASSIN 49 Dose Ranging Study 49 NEBIDO R 49 Zalbin 49 Qtrly Avg 49 Xyzal 49 HIV integrase inhibitor 49 carfilzomib 49 Promacta 49 TopoTarget 49 BLP# Liposome Vaccine 49 BioSante Pharmaceuticals 49 #FY 49 Immunogen 49 Bosutinib 49 Sirion Therapeutics 49 EGS# 48 Telatinib 48 Arxxant 48 Arranon 48 Rezonic 48 Reports Narrower Loss 48 TAXUS ATLAS 48 AMEX DDD 48 Fortesta 48 Junovan TM 48 Azedra 48 KRN# 48 P#X# antagonist 48 Neurocrine 48 evaluating T DM1 48 Pierre Fabre Medicament 48 generation purine nucleoside 48 asenapine 48 Betaferon 48 VESTASYNC 48 Bremelanotide 48 FQ2 48 MORAb 48 antibody MAb 48 MIVI III 48 pivotal Phase 48 Phase 2b Trial 48 licensee AnGes MG 48 Palatin Technologies 48 Treanda 48 vinflunine 48 Reaffirms FY# 48 Nasdaq GPCB 48 Affinitak 48 CDP# 48 riociguat 48 Increlex ® 48 Intermune 48 Silodosin 48 Sciele 48 Safinamide 48 RAV# 48 Medigene 48 INT# [002] 48 ARDIS 48 miconazole Lauriad ® 48 Array BioPharma 48 ORE# 48 Premarket Approval PMA 48 Cadence Pharmaceuticals 48 Targanta 48 Risperidone Oral Solution 48 Plenaxis TM 48 Biological License Application 48 HuCAL antibodies 48 Provenge prostate cancer 48 Praecis 48 Alnara Pharmaceuticals 48 preclinical toxicology 48 E1 INT TM 48 LymphoStat B TM 48 Jerini 48 Anturol ® 48 ABSORB trial 48 Onsolis 48 Lilly LLY 48 Upcoming Milestones 48 XL# XL# XL# 48 MONOVISC 48 efficacy endpoint 48 Guanilib 48 Lovaza TM 48 CCR5 antagonist 48 Augment Bone Graft 48 Zingo TM 48 Certriad 48 sNDA 48 PRTX 48 Presents Positive Preclinical 48 CD# CEA 48 JAK2 inhibitor 48 sumatriptan DosePro 48 TLR8 agonist 48 Excellagen 48 Galvus 48 Lifts FY# Guidance 48 Commences Phase 48 Backs FY# 48 Oasmia 48 Joulferon 48 RESULTS PHONE NO 48 Zelrix 48 oral anticancer 48 Phase II 48 semagacestat 48 Net Profit Soars 48 Fast Track Status 48 CyDex Pharmaceuticals 48 subcutaneous formulation 48 NADiA ProsVue 48 Alaven 48 ALN TTR# 48 Iluvien ® 48 Virulizin 48 BEMA Fentanyl 48 gaboxadol 48 NuPathe 48 FDA APPROVES 48 MBP# [001] 48 CEQ# 48 Phase Ib Clinical Trial 48 investigational pan BCR 48 ATPace TM 48 Biopharmaceuticals AG 48 Tops Ests 48 dose escalation trial 48 CaPre TM 48 QTinno TM 48 Linjeta 48 BUSINESS OUTLOOK 48 Prednisporin TM 48 Fusilev 48 candidate REP# 48 Zyflo 48 Albuferon Phase 48 Net Loss Narrows 48 Q3 Profit Plummets 47 Tamibarotene 47 Phase III clinical trials 47 NASDAQ INGN 47 VICTOR E1 47 Doryx 47 TKB# 47 prucalopride 47 Balaglitazone 47 Cutanea 47 Shigamabs R 47 KuDOS 47 investigational oral hepatitis C 47 Submits Investigational 47 Premarket Approval Application 47 Pegintron 47 FY# EPS Outlook 47 Lyrica pregabalin 47 refractory acute lymphocytic 47 ALTANA Pharma 47 preclinical 47 aurora kinase 47 Humira adalimumab 47 Salmedix 47 Carrols Restaurant 47 Orphan Status 47 Wellstat 47 bazedoxifene conjugated estrogens 47 PF # [001] 47 Acetavance TM 47 IIa clinical trial 47 Relistor 47 Drug Eluting Stent System 47 Zavesca 47 PIX# trial 47 Fareston 47 Karo Bio 47 Coreg CR 47 mitogen activated ERK kinase 47 Deferiprone 47 Reports Narrower 47 Roche RHHBY 47 prGCD 47 Onyx Pharmaceuticals Inc 47 generic gabapentin 47 blood thinner prasugrel 47 Replagal 47 Sycrest 47 LHRH antagonist 47 Douglas Petkus 47 Cipralex 47 Application BLA 47 IMGN# 47 oral proteasome inhibitor 47 TRC# 47 PNP inhibitor 47 reiterates FY 47 Mycamine 47 Celgosivir 47 SYCREST 47 Circ Pharma 47 #QF# 47 PD LID 47 relapsed refractory multiple myeloma 47 ACHN 47 Sciele Pharma 47 selective estrogen receptor modulator 47 Files IND 47 Stanicky 47 Hedgehog pathway inhibitor 47 Eraxis 47 KAI Pharmaceuticals 47 Onalta ™ 47 Tenthoff 47 Phase IIa clinical trials 47 CONSERV 47 Angeliq 47 resultsof 47 JAK1 47 AZX# Phase 47 palifosfamide 47 Fournier Pharma 47 Portola Pharmaceuticals 47 Phase 2a Trial 47 Daclizumab 47 EGOC 47 Cintredekin Besudotox 47 clinical trial 47 GSK 47 clinical 47 Entereg TM